FDA OKs compassionate use of Mesoblast stem cells in kids’ Covid-19 complications

Mesoblast (NASDAQ:MESO) initiates an expanded access protocol (EAP) in the U.S. for compassionate use of its allogeneic mesenchymal stem cell product candidate, remestemcel-L, in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome (MIS-C).

Patients aged between two months and 17 years may receive one or two doses of remestemcel-L within five days of referral under the EAP.

https://seekingalpha.com/news/3588616-fda-oks-compassionate-use-of-mesoblast-stem-cells-in-children-covidminus-19-complications